What do systematic reviews say?

Intervention not reported

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 135 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in raised cholesterol (moderate certainty).

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  RR 6.03 [0.75, 48.78]
  1 study · 64 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in mortality (moderate certainty).

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  RR 0.84 [0.59, 1.19]
  8 studies · 2317 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in progression to AIDS (moderate certainty).

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  RR 1.23 [0.72, 2.11]
  5 studies · 2005 participants
  Moderate

Intervention not reported

It is very uncertain whether the intervention changes all severe adverse events (very low certainty).

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  RR 0.91 [0.71, 1.18]
  8 studies · 2329 participants
  Very low

Intervention not reported

The intervention showed no clear difference in discontinuation rate (moderate certainty).

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  RR 0.93 [0.69, 1.25]
  9 studies · 2384 participants
  Moderate

Intervention not reported

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1829 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in treatment failure (low certainty).

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  RR 0.97 [0.76, 1.24]
  5 studies · 737 participants
  Low

Intervention not reported

The intervention probably leads to higher severe adverse events: central nervous system (moderate certainty).

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  RR 4.46 [1.65, 12.03]
  6 studies · 2049 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in severe adverse events: gastrointestinal (low certainty).

• Efavirenz or nevirapine in three‐drug combination therapy with two nucleoside or nucleotide‐reverse transcriptase… 2016 · Cochrane Headline outcomes only
  RR 0.76 [0.48, 1.21]
  6 studies · 2049 participants
  Low

Intervention not reported

• Tools developed and disseminated by guideline producers to promote the uptake of their guidelines 2016 · Cochrane Headline outcomes only
  no estimate extracted
  68 participants
  Moderate

Intervention not reported

• Tools developed and disseminated by guideline producers to promote the uptake of their guidelines 2016 · Cochrane Headline outcomes only
  no estimate extracted
  68 participants
  Low

SSRIs or SNRIs vs placebo

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 113 participants
  Low

SSRIs or SNRIs vs amitriptyline

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 104 participants
  Low

SSRIs or SNRIs vs amitriptyline

The review found no eligible studies for this question.

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SSRIs or SNRIs vs amitriptyline

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 62 participants
  Very low

SSRIs or SNRIs vs amitriptyline

The review found no eligible studies for this question.

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SSRIs or SNRIs vs amitriptyline

SSRIs or SNRIs showed no clear difference in withdrawn (for any reasons and due to adverse events) compared with amitriptyline (low certainty).

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  OR 0.39 [0.1, 1.5]
  1 study · 64 participants
  Low

SSRIs or SNRIs vs placebo

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 113 participants
  Low

SSRIs or SNRIs vs placebo

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 60 participants
  GRADE not reported